Vizient Medical Device Tech Watch Highlights Rapid Adoption of AI-Enabled Stroke Detection

Data analysis from the Vizient, Inc. Clinical Data Base shows a rapid uptake in the use of artificial intelligence (AI) for detection of ischemic stroke. The data is highlighted in the latest edition of Vizient’s Medical Device Tech Watch. In addition, the publication offers insights on the shift of spine and orthopedics from hospital inpatient to ambulatory surgery centers as well as a perspective on improving surgical preference card management. The publication can be accessed here.

“This year has brought about many opportunities to partner strategically and collaborate across organizations to tackle obstacles in health care,” said Erik Axter, managing principal, physician preference, Vizient. “We are excited about the new technologies and solutions emerging to help solve these challenges and advance our industry, particularly in complex categories like cardiology and orthopedics.”

Featured articles include:

AI-enabled ischemic stroke detection, triage and notification—Quick intervention for an intracranial large-vessel occlusion (LVO), a common type of ischemic stroke, can improve patient outcomes. With the AI process, an interventionalist could conceivably receive the LVO image on their mobile phone, evaluate the scan and begin booking the procedure immediately. On October 1, 2020, the Centers for Medicare & Medicaid Services (CMS) implemented a reimbursement policy for AI-based LVO detection. By the first quarter of 2021, analysis of the Vizient Clinical Data Base showed, the number of Vizient members using the AI technology doubled.

The shift to ambulatory orthopedic and spine procedures moves suppliers to ramp up provider support—ASC procedural volume continues to accelerate, fueled by CMS policy changes, commercial payer steerage, patient preference and pressure to reduce costs. Data from Sg2, a Vizient company, predicts outpatient hip and knee replacements to increase by 75% over the next several years. Manufacturers are responding to the current and future growth by expanding their service line and technology offerings to support ASC performance.

How one health system improved supply availability and accuracy by optimizing their surgical preference card database—Inaccurate surgical preference cards were negatively affecting surgeon and staff satisfaction and slowing turnaround times in the OR of a large academic medical. To address this issue, they developed a sustainable process for managing the cards, increasing staff confidence in their accuracy and ensuring the OR is properly equipped prior to each procedure, improving efficiency as well as patient safety.

Medical Device News Magazine
Our publication is dedicated to bringing our readers the latest medical device news. We are proud to boast that our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall purpose and objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

Data from clinical studies of STK-001 demonstrated clinical benefit for patients ages 2 to 18 years old, including reductions in seizures and improvements in cognition and behavior that support the potential for disease modificatio. Analysis of 72 patients treated in STK-001 clinical trials suggests that higher STK-001 drug exposure in brain leads to greater seizure reductions. Two-year data from the longest prospective natural history study of Dravet syndrome showed that, on average, patients experienced no meaningful improvement in convulsive seizure frequency and exhibited widening gaps in cognition and behavior despite treatment with the best available anti-seizure medicines.
"Exact Sciences is looking forward to presenting new evidence at SABCS that adds important perspectives to treating breast cancer patients and showing that some patients may be able to de-escalate treatments and still have positive outcomes," said Dr. Rick Baehner, Chief Medical Officer, Precision Oncology, Exact Sciences. "Every year, we build upon the precedent set by the Oncotype DX Breast Recurrence Score® test and its prognostic and predictive abilities to determine the chemotherapy benefit for specific breast cancer patients. We are pleased to see authorities expanding access to this test as we continue to develop key evidence in collaboration with some of the world's most prestigious, breast cancer-focused organizations."
Clozapine has been established as the most effective antipsychotic medication for treatment-resistant schizophrenia. However, it is significantly underutilized mainly due to the risk of developing agranulocytosis and the need to frequently monitor the absolute neutrophil count (ANC).
Dagi-Ben Noon, CEO of Inspira Technologies, reflects on the partnership's significance: "By Integrating our technology to oxygenate blood directly with Ennocure's infection prevention solutions, we are focusing on potentially improving patient outcomes in ICUs and paving the way for safer, more effective life-support treatments. This collaboration is expected to accelerate the development and broaden the implementation of our advanced technology."
The findings suggest that the novel, non-invasive genomic test can help physicians guide next steps for these patients, enabling them to potentially avoid unnecessary invasive procedures or accelerate time to appropriate treatment.

By using this website you agree to accept Medical Device News Magazine Privacy Policy